Skip to main content
Top
Published in: Trials 1/2012

Open Access 01-12-2012 | Methodology

Should we reconsider the routine use of placebo controls in clinical research?

Authors: Andrew L Avins, Daniel C Cherkin, Karen J Sherman, Harley Goldberg, Alice Pressman

Published in: Trials | Issue 1/2012

Login to get access

Abstract

Background

Modern clinical-research practice favors placebo controls over usual-care controls whenever a credible placebo exists. An unrecognized consequence of this preference is that clinicians are more limited in their ability to provide the benefits of the non-specific healing effects of placebos in clinical practice.

Methods

We examined the issues in choosing between placebo and usual-care controls. We considered why placebo controls place constraints on clinicians and the trade-offs involved in the choice of control groups.

Results

We find that, for certain studies, investigators should consider usual-care controls, even if an adequate placebo is available. Employing usual-care controls would be of greatest value for pragmatic trials evaluating treatments to improve clinical care and for which threats to internal validity can be adequately managed without a placebo-control condition.

Conclusions

Intentionally choosing usual-care controls, even when a satisfactory placebo exists, would allow clinicians to capture the value of non-specific therapeutic benefits that are common to all interventions. The result could be more effective, patient-centered care that makes the best use of both specific and non-specific benefits of medical interventions.
Appendix
Available only for authorised users
Literature
1.
go back to reference Hrobjartsson A, Gotzsche PC: Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. N Engl J Med. 2001, 344: 1594-1602. 10.1056/NEJM200105243442106.CrossRefPubMed Hrobjartsson A, Gotzsche PC: Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. N Engl J Med. 2001, 344: 1594-1602. 10.1056/NEJM200105243442106.CrossRefPubMed
2.
go back to reference Miller FG, Rosenstein DL: The nature and power of the placebo effect. J Clin Epidemiol. 2006, 59: 331-335. 10.1016/j.jclinepi.2005.12.001.CrossRefPubMed Miller FG, Rosenstein DL: The nature and power of the placebo effect. J Clin Epidemiol. 2006, 59: 331-335. 10.1016/j.jclinepi.2005.12.001.CrossRefPubMed
3.
go back to reference Ernst E: Placebo: new insights into an old enigma. Drug Discov Today. 2007, 12: 413-418. 10.1016/j.drudis.2007.03.007.CrossRefPubMed Ernst E: Placebo: new insights into an old enigma. Drug Discov Today. 2007, 12: 413-418. 10.1016/j.drudis.2007.03.007.CrossRefPubMed
4.
go back to reference Greene PJ, Wayne PM, Kerr CE, Weiger WA, Jacobson E, Goldman P, Kaptchuk TJ: The powerful placebo: doubting the doubters. Adv Mind Body Med. 2001, 17: 298-307. discussion 312–318PubMed Greene PJ, Wayne PM, Kerr CE, Weiger WA, Jacobson E, Goldman P, Kaptchuk TJ: The powerful placebo: doubting the doubters. Adv Mind Body Med. 2001, 17: 298-307. discussion 312–318PubMed
6.
go back to reference Colloca L, Benedetti F: Placebos and painkillers: is mind as real as matter?. Nat Rev Neurosci. 2005, 6: 545-552. 10.1038/nrn1705.CrossRefPubMed Colloca L, Benedetti F: Placebos and painkillers: is mind as real as matter?. Nat Rev Neurosci. 2005, 6: 545-552. 10.1038/nrn1705.CrossRefPubMed
7.
go back to reference Benedetti F, Amanzio M, Maggi G: Potentiation of placebo analgesia by proglumide. Lancet. 1995, 346: 1231-10.1016/S0140-6736(95)92938-X.CrossRefPubMed Benedetti F, Amanzio M, Maggi G: Potentiation of placebo analgesia by proglumide. Lancet. 1995, 346: 1231-10.1016/S0140-6736(95)92938-X.CrossRefPubMed
8.
go back to reference Sherman R, Hickner J: Academic physicians use placebos in clinical practice and believe in the mind-body connection. J Gen Intern Med. 2008, 23: 7-10.CrossRefPubMed Sherman R, Hickner J: Academic physicians use placebos in clinical practice and believe in the mind-body connection. J Gen Intern Med. 2008, 23: 7-10.CrossRefPubMed
9.
go back to reference Tilburt JC, Emanuel EJ, Kaptchuk TJ, Curlin FA, Miller FG: Prescribing “placebo treatments”: results of national survey of US internists and rheumatologists. BMJ. 2008, 337: a1938-10.1136/bmj.a1938.CrossRefPubMedPubMedCentral Tilburt JC, Emanuel EJ, Kaptchuk TJ, Curlin FA, Miller FG: Prescribing “placebo treatments”: results of national survey of US internists and rheumatologists. BMJ. 2008, 337: a1938-10.1136/bmj.a1938.CrossRefPubMedPubMedCentral
10.
11.
13.
go back to reference Kaptchuk TJ, Friedlander E, Kelley JM, Sanchez MN, Kokkotou E, Singer JP, Kowalczykowski M, Miller FG, Kirsch I, Lembo AJ: Placebos without deception: a randomized controlled trial in irritable bowel syndrome. PLoS One. 2010, 5: e15591-10.1371/journal.pone.0015591.CrossRefPubMedPubMedCentral Kaptchuk TJ, Friedlander E, Kelley JM, Sanchez MN, Kokkotou E, Singer JP, Kowalczykowski M, Miller FG, Kirsch I, Lembo AJ: Placebos without deception: a randomized controlled trial in irritable bowel syndrome. PLoS One. 2010, 5: e15591-10.1371/journal.pone.0015591.CrossRefPubMedPubMedCentral
14.
go back to reference Schwartz D, Lellouch J: Explanatory and pragmatic attitudes in therapeutical trials. J Chronic Dis. 1967, 20: 637-648. 10.1016/0021-9681(67)90041-0.CrossRefPubMed Schwartz D, Lellouch J: Explanatory and pragmatic attitudes in therapeutical trials. J Chronic Dis. 1967, 20: 637-648. 10.1016/0021-9681(67)90041-0.CrossRefPubMed
15.
go back to reference Estrada CA, Young MJ: Patient preferences for novel therapy: an N-of-1 trial of garlic in the treatment for hypertension. J Gen Intern Med. 1993, 8: 619-621. 10.1007/BF02599719.CrossRefPubMed Estrada CA, Young MJ: Patient preferences for novel therapy: an N-of-1 trial of garlic in the treatment for hypertension. J Gen Intern Med. 1993, 8: 619-621. 10.1007/BF02599719.CrossRefPubMed
16.
go back to reference Cook DJ: Randomized trials in single subjects: the N of 1 study. Psychopharmacol Bull. 1996, 32: 363-367.PubMed Cook DJ: Randomized trials in single subjects: the N of 1 study. Psychopharmacol Bull. 1996, 32: 363-367.PubMed
17.
go back to reference Vickers AJ, de Craen AJ: Why use placebos in clinical trials? A narrative review of the methodological literature. J Clin Epidemiol. 2000, 53: 157-161. 10.1016/S0895-4356(99)00139-0.CrossRefPubMed Vickers AJ, de Craen AJ: Why use placebos in clinical trials? A narrative review of the methodological literature. J Clin Epidemiol. 2000, 53: 157-161. 10.1016/S0895-4356(99)00139-0.CrossRefPubMed
18.
go back to reference Linde K, Allais G, Brinkhaus B, Manheimer E, Vickers A, White AR: Acupuncture for migraine prophylaxis. Cochrane Database Syst Rev. 2009, 1: CD001218-PubMed Linde K, Allais G, Brinkhaus B, Manheimer E, Vickers A, White AR: Acupuncture for migraine prophylaxis. Cochrane Database Syst Rev. 2009, 1: CD001218-PubMed
19.
go back to reference Furlan AD, van Tulder M, Cherkin D, Tsukayama H, Lao L, Koes B, Berman B: Acupuncture and dry-needling for low back pain: an updated systematic review within the framework of the cochrane collaboration. Spine (Phila Pa 1976). 2005, 30: 944-963. 10.1097/01.brs.0000158941.21571.01.CrossRef Furlan AD, van Tulder M, Cherkin D, Tsukayama H, Lao L, Koes B, Berman B: Acupuncture and dry-needling for low back pain: an updated systematic review within the framework of the cochrane collaboration. Spine (Phila Pa 1976). 2005, 30: 944-963. 10.1097/01.brs.0000158941.21571.01.CrossRef
21.
go back to reference Omar MA, Wilson JP, Cox TS: Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother. 2001, 35: 1096-1107.CrossRefPubMed Omar MA, Wilson JP, Cox TS: Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother. 2001, 35: 1096-1107.CrossRefPubMed
22.
go back to reference Hlatky MA: Expanding the orbit of primary prevention–moving beyond JUPITER. N Engl J Med. 2008, 359: 2280-2282. 10.1056/NEJMe0808320.CrossRefPubMed Hlatky MA: Expanding the orbit of primary prevention–moving beyond JUPITER. N Engl J Med. 2008, 359: 2280-2282. 10.1056/NEJMe0808320.CrossRefPubMed
23.
go back to reference Hrobjartsson A, Kaptchuk TJ, Miller FG: Placebo effect studies are susceptible to response bias and to other types of biases. J Clin Epidemiol. 2011, 64: 1223-1229. 10.1016/j.jclinepi.2011.01.008.CrossRefPubMedPubMedCentral Hrobjartsson A, Kaptchuk TJ, Miller FG: Placebo effect studies are susceptible to response bias and to other types of biases. J Clin Epidemiol. 2011, 64: 1223-1229. 10.1016/j.jclinepi.2011.01.008.CrossRefPubMedPubMedCentral
24.
go back to reference Furberg B, Furberg C: Why is blinding/masking so important?. Evaluating clinical research. 2007, Springer, New York, 10- Furberg B, Furberg C: Why is blinding/masking so important?. Evaluating clinical research. 2007, Springer, New York, 10-
25.
go back to reference Dieppe P: Osteoarthritis of the knee in primary care. BMJ. 2008, 336: 105-106. 10.1136/bmj.39412.592477.80.CrossRefPubMed Dieppe P: Osteoarthritis of the knee in primary care. BMJ. 2008, 336: 105-106. 10.1136/bmj.39412.592477.80.CrossRefPubMed
27.
go back to reference Kupperman HS, Wetchler BB, Blatt MH: Contemporary therapy of the menopausal syndrome. J Am Med Assoc. 1959, 171: 1627-1637. 10.1001/jama.1959.03010300001001.CrossRefPubMed Kupperman HS, Wetchler BB, Blatt MH: Contemporary therapy of the menopausal syndrome. J Am Med Assoc. 1959, 171: 1627-1637. 10.1001/jama.1959.03010300001001.CrossRefPubMed
Metadata
Title
Should we reconsider the routine use of placebo controls in clinical research?
Authors
Andrew L Avins
Daniel C Cherkin
Karen J Sherman
Harley Goldberg
Alice Pressman
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Trials / Issue 1/2012
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/1745-6215-13-44

Other articles of this Issue 1/2012

Trials 1/2012 Go to the issue